Drug Trial Radar · NCT07590934
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
152
Planned (sponsor's estimate)
Start
Jun 3, 2026
Primary completion
Sep 25, 2029
Study completion Sep 25, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- May 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of multiple anti-cancer agents in participants with metastatic prostate cancer.
Conditions
- Metastatic Prostate Cancer
Interventions
AZD2265 (FPI-2265)Drug
AZD2265 (FPI-2265) will be administered as an intravenous (IV) injection.
Palacaparib (AZD9574)Drug
Palacaparib (AZD9574) will be administered orally.
DocetaxelDrug
Docetaxel will be administered as an IV infusion.
AZD2287 (Imaging agent)Drug
AZD2287 will be administered as an IV injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number of participants with treatment-emergent adverse events (TEAEs)including serious adverse events (SAEs), treatment-related AEs (TRAEs) and adverse events of special interests (AESIs)Time frame: Up to approximately 1 year after last dose
- Part A: Number of participants with dose limiting toxicities (DLTs)Time frame: From date of first dose up to approximately 2 cycles (up to 3 months)
- Part B: Number of participants with TEAEsTime frame: Up to approximately 1 year after last dose
- Part B: Prostate Specific Antigen 50 (PSA50) response rateTime frame: Up to 3 years 4 months
Locations
38 sites in 7 countries. Site status is shown where the registry gives one.
Research Site
Duarte, California · Not yet recruiting
Research Site
Encino, California · Not yet recruiting
Research Site
South Pasadena, California · Recruiting
Research Site
Miami, Florida · Recruiting
Research Site
Orlando, Florida · Not yet recruiting
Research Site
Tampa, Florida · Not yet recruiting
Research Site
Metairie, Louisiana · Not yet recruiting
Research Site
Minneapolis, Minnesota · Not yet recruiting
Research Site
Omaha, Nebraska · Recruiting
Research Site
New York, New York · Not yet recruiting
Research Site
Portland, Oregon · Not yet recruiting
Research Site
Houston, Texas · Not yet recruiting
Research Site
North Adelaide, Australia · Not yet recruiting
Research Site
Essen, Germany · Not yet recruiting
Research Site
Jena, Germany · Not yet recruiting
Research Site
Rostock, Germany · Not yet recruiting
Research Site
Tübingen, Germany · Not yet recruiting
Research Site
Bergamo, Italy · Not yet recruiting
Research Site
Meldola, Italy · Not yet recruiting
Research Site
Milan, Italy · Not yet recruiting
Research Site
Milan, Italy · Not yet recruiting
Research Site
Roma, Italy · Not yet recruiting
Research Site
Seoul, South Korea · Not yet recruiting
Research Site
Seoul, South Korea · Not yet recruiting
Research Site
Seoul, South Korea · Not yet recruiting
Research Site
Seoul, South Korea · Not yet recruiting
Research Site
Seoul, South Korea · Withdrawn
Research Site
Barcelona, Spain · Not yet recruiting
Research Site
L'Hospitalet de Llobregat, Spain · Not yet recruiting
Research Site
Madrid, Spain · Not yet recruiting
Research Site
Madrid, Spain · Not yet recruiting
Research Site
Pamplona, Spain · Not yet recruiting
Research Site
Belfast, United Kingdom · Not yet recruiting
Research Site
Fulham, United Kingdom · Not yet recruiting
Research Site
Guildford, United Kingdom · Not yet recruiting
Research Site
London, United Kingdom · Not yet recruiting
Research Site
Newcastle upon Tyne, United Kingdom · Not yet recruiting
Research Site
Oxford, United Kingdom · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.